The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Check the time stamp on this data. Updated AI-Generated Signals for Iteos Therapeutics Inc. (ITOS) available here: ITOS.

Wells Fargo has recently initiated iTeos Therapeutics Inc (ITOS) stock to Overweight rating, as announced on August 13, 2024, according to Finviz. Earlier, on May 5, 2021, H.C. Wainwright had ...

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Results for Pfizer’s ponsegromab looked promising, while BioNTech and Instil Bio capitalized on momentum surrounding a kind of bispecific antibody.

Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...

iTeos Therapeutics shares dipped 13.7% to $14.40 in pre-market trading. Here are some big stocks recording losses in today's ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer.

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The ...

Shares of Exicure, Inc. XCUR rose sharply in today's pre-market trading after the company entered into debt-for-equity ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...